← Back to Clinical Trials
Recruiting NCT06946498

NCT06946498 First Local Anaesthesia Thoracoscopy for Pleural Effusion Diagnosis.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06946498
Status Recruiting
Phase
Sponsor National and Kapodistrian University of Athens
Condition Suspected Malignant Lung Neoplasm
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2023-05-23
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 90 Years
Study Type INTERVENTIONAL
Interventions
Local Anesthesia ThoracoscopyPleuroscopy with Rigid Thoracoscope and Forceps biopsies

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2023-05-23 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Non randomized study with two groups. The study group includes patients with suspected malignant pleural effusion, in whom the investigation of pleural effusion begins directly with pleural biopsy by Local Anesthesia Thoracoscopy (LAT). The Control Group includes patients who come to the same hospital and are treated with the Standard of Care (SOC) strategies were used. Efficacy of LAT, Sensitivity, Hospitalization, time to diagnosis and general safety and comfort of the groups' subjects will be assessed.

Eligibility Criteria

Inclusion Criteria: * Undiagnosed pleural effusion with the character of a lymphocytic exudate Exclusion Criteria: * Empyema * Transudate pleural effusion. * Central airway obstruction by tumor. * Existence of extensive adhesions that do not allow the development of iatrogenic pneumothorax and the safe entry of the thoracoscope. * Uncontrollable cough. * Acute respiratory failure and/or Hypercapnia. * Performance Status: 5

Contact & Investigator

Central Contact

Nektarios ANAGNOSTOPOULOS, Ass. professor

✉ aris.anag@yahoo.gr

📞 +306946869480

Principal Investigator

Grigorios Stratakos, Professor

STUDY DIRECTOR

National and Kapodistrian University of Athens

Frequently Asked Questions

Who can join the NCT06946498 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Suspected Malignant Lung Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06946498 currently recruiting?

Yes, NCT06946498 is actively recruiting participants. Contact the research team at aris.anag@yahoo.gr for enrollment information.

Where is the NCT06946498 trial being conducted?

This trial is being conducted at Athens, Greece.

Who is sponsoring the NCT06946498 clinical trial?

NCT06946498 is sponsored by National and Kapodistrian University of Athens. The principal investigator is Grigorios Stratakos, Professor at National and Kapodistrian University of Athens. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology